MRVI
MARAVAI LIFESCIENCES HOLDINGS, INC.
$5.02
+0.60%
$1.3B
No data for this timeframe.
Vol
Market Cap$1.3B
Cap SizeSmall Cap
Analyst ConsensusBuy (63%)
Inst. Holders8 funds
Inst. Value$57.0M
Inst. Activity1 buys / 2 sells
SEC Reports3
Recent Activity
Jun 3, 2026
SEC
Maravai LifeSciences refinanced its prior credit agreement by entering into a new $150.0 million term loan and $30.0 mil
8-K — Impact 6/10
May 26, 2026
Insider
DeFord John A sold 46,293 shares
Director @ $0.00 ($0.00)
May 26, 2026
Insider
CUNNINGHAM SEAN LAURENCE sold 46,293 shares
Director @ $0.00 ($0.00)
May 26, 2026
Insider
MARKER LUKE JOSEPH sold 46,293 shares
Director @ $0.00 ($0.00)
May 7, 2026
earnings_calendar
MRVI Q1 2026 Earnings After Market Close — 2026-05-07
Apr 28, 2026
SEC
Maravai LifeSciences Holdings, Inc. filed a DEFA14A to add Inline XBRL tagging to its definitive proxy statement for the
DEFA14A — Impact 1/10
Feb 25, 2026
SEC
Maravai LifeSciences reported full-year 2025 revenue of $185.7 million, down 28.3% year-over-year, driven by a 39.0% dec
8-K — Impact 6/10
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
845,408 shares ($2.7M)
Price Targets
$5.70
+13.5% upside
Buy
Current $5.02
Low $5.00
Median $6.00
High $6.00
5 analysts
$5.00
$6.00
Analyst Ratings
4Strong Buy
6Buy
6Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Dec 15, 2025 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Aug 12, 2025 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Aug 12, 2025 | Craig-Hallum | MAINTAIN | Buy → Buy |
| May 13, 2025 | Craig-Hallum | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next Q | $-0.05 ▲ +5.7% | $-0.06 — $-0.03 | 42% YoY | 7 |
| Current FY | $-0.11 ▲ +38.0% | $-0.17 — $-0.07 | 60% YoY | 8 |
| Current Q | $-0.04 ▲ +5.1% | $-0.06 — $-0.03 | 45% YoY | 8 |
| Next FY | $-0.09 ▲ +38.7% | $-0.23 — $0.00 | 19% YoY | 8 |
Latest Reports
BULLISH
8-K
6/10
Maravai LifeSciences refinanced its prior credit agreement by entering into a new $150.0 million term loan and $30.0 mil
Jun 3, 2026
NEUTRAL
DEFA14A
1/10
Maravai LifeSciences Holdings, Inc. filed a DEFA14A to add Inline XBRL tagging to its definitive proxy statement for the
Apr 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $23.3M | — |
| RENAISSANCE TECHNOLOGIES LLC | $13.7M | — |
| MORGAN STANLEY | $11.2M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $3.2M | NEW |
| TWO SIGMA INVESTMENTS, LP | $2.7M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 26, 2026 | DeFord John | A | $0.00 |
| May 26, 2026 | CUNNINGHAM SEAN | A | $0.00 |
| May 26, 2026 | MARKER LUKE | A | $0.00 |
| May 26, 2026 | GRAY SUSANNAH | A | $0.00 |
| May 26, 2026 | MIHAS CONSTANTINE | A | $0.00 |
8 institutional holders with $57.0M total value (17,531,924 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 7,166,528 | $23.3M | 40.9% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 4,225,089 | $13.7M | 24.1% | — |
| 3 | MORGAN STANLEY | 3,446,802 | $11.2M | 19.7% | ADD +56.9% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 988,040 | $3.2M | 5.6% | NEW |
| 5 | TWO SIGMA INVESTMENTS, LP | 845,408 | $2.7M | 4.8% | TRIM -27.9% |
| 6 | BANK OF AMERICA CORP /DE/ | 701,714 | $2.3M | 4.0% | TRIM -51.0% |
| 7 | WELLS FARGO & COMPANY/MN | 123,034 | $399.9K | 0.7% | ADD +46.0% |
| 8 | FMR LLC | 35,309 | $114.8K | 0.2% | ADD +26.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,172,248 | 845,408 | -27.9% | $2.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,432,364 | 701,714 | -51.0% | $2.3M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 84,291 | 123,034 | +46.0% | $399.9K | 2025-Q4 |
| UBS Group AG | TRIM | 3,232,284 | 2,399,212 | -25.8% | $6.9M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,029,645 | 1,432,364 | +39.1% | $4.1M | 2025-Q3 |
| FMR LLC | ADD | 26,323 | 33,370 | +26.8% | $95.8K | 2025-Q3 |
| UBS Group AG | DOUBLED | 555,453 | 3,232,284 | +481.9% | $7.8M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 53,849 | 79,237 | +47.1% | $191.0K | 2025-Q2 |
| FMR LLC | TRIM | 41,370 | 26,323 | -36.4% | $63.4K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 109,419 | 1,434,471 | +1211.0% | $3.2M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 101,569 | 1,125,497 | +1008.1% | $2.5M | 2025-Q1 |
| UBS Group AG | TRIM | 1,951,143 | 555,453 | -71.5% | $1.2M | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 2,129,451 | 41,370 | -98.1% | $91.4K | 2025-Q1 |
| UBS Group AG | DOUBLED | 233,372 | 1,951,143 | +736.1% | $10.6M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 44,400 | 101,569 | +128.8% | $553.6K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 37,684 | 52,685 | +39.8% | $287.1K | 2024-Q4 |
| MORGAN STANLEY | ADD | 1,720,348 | 2,699,739 | +56.9% | $22.4M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 946,576 | — | $7.9M | 2024-Q3 |
9 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 26, 2026 | DeFord John A | Director | A | 46,293 | $0.00 | $0.00 |
| May 26, 2026 | CUNNINGHAM SEAN LAURENCE | Director | A | 46,293 | $0.00 | $0.00 |
| May 26, 2026 | MARKER LUKE JOSEPH | Director | A | 46,293 | $0.00 | $0.00 |
| May 26, 2026 | GRAY SUSANNAH | Director | A | 46,293 | $0.00 | $0.00 |
| May 26, 2026 | MIHAS CONSTANTINE S | Director | A | 46,293 | $0.00 | $0.00 |
| May 26, 2026 | ECKERT R ANDREW | Director | A | 46,293 | $0.00 | $0.00 |
| May 26, 2026 | LUCIER GREGORY T | Director | A | 46,293 | $4.38 | $202.8K |
| May 26, 2026 | LUCIER GREGORY T | Director | A | 46,293 | $0.00 | $0.00 |
| May 15, 2026 | Dolan Christine | See Remarks | A | 5,006 | $1.79 | $9.0K |
| May 15, 2026 | ORESHACK KURT | General Counsel | A | 776 | $2.84 | $2.2K |
| Mar 16, 2026 | ORESHACK KURT | General Counsel | F | 39,976 | $3.08 | $123.1K |
| Mar 16, 2026 | Dolan Christine | See Remarks | F | 28,661 | $3.08 | $88.3K |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 4.3/10.
BULLISH
8-K
6/10
Maravai LifeSciences refinanced its prior credit agreement by entering into a new $150.0 million ter
Jun 3, 2026
NEUTRAL
DEFA14A
1/10
Maravai LifeSciences Holdings, Inc. filed a DEFA14A to add Inline XBRL tagging to its definitive pro
Apr 28, 2026
MIXED
8-K
6/10
Maravai LifeSciences reported full-year 2025 revenue of $185.7 million, down 28.3% year-over-year, d
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (63% buy). Based on 16 analysts: 4 strong buy, 6 buy, 6 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.70 mean target
+13.5% upside
Buy (1.75)
$5.00 Low
$6.00 High
| Metric | Value |
|---|---|
| Current Price | $5.02 |
| Target Low | $5.00 |
| Target Mean | $5.70 |
| Target Median | $6.00 |
| Target High | $6.00 |
| # Analysts | 5 |
| Recommendation | Buy (1.75) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next Q 2026-09-30 |
$-0.05 | $-0.06 | $-0.03 | 41.9% | +5.7% | 1↑ 0↓ | $0.0B | 6.3% | 7 |
| Current FY 2026-12-31 |
$-0.11 | $-0.17 | $-0.07 | 60.4% | +38.0% | 2↑ 0↓ | $0.2B | 13.3% | 8 |
| Current Q 2026-06-30 |
$-0.04 | $-0.06 | $-0.03 | 45.0% | +5.1% | 0↑ 1↓ | $0.0B | 2.7% | 8 |
| Next FY 2027-12-31 |
$-0.09 | $-0.23 | $0.00 | 19.0% | +38.7% | 2↑ 0↓ | $0.2B | 7.3% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.044 | |
| 7d ago | $-0.047 | +0.003 |
| 30d ago | $-0.046 | +0.002 |
| 60d ago | $-0.045 | +0.001 |
| 90d ago | $-0.045 | +0.001 |
14 analyst firms have rated this stock: 1 upgrades, 8 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Dec 15, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Aug 12, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Aug 12, 2025 | Craig-Hallum | MAINTAIN | Buy | Buy |
| May 13, 2025 | Craig-Hallum | MAINTAIN | Buy | Buy |
| May 13, 2025 | Baird | MAINTAIN | Neutral | Neutral |
| Mar 25, 2025 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 21, 2025 | UBS | MAINTAIN | Neutral | Neutral |
| Mar 3, 2025 | B of A Securities | MAINTAIN | Buy | Buy |
| Feb 26, 2025 | Baird | DOWNGRADE | Outperform | Neutral |
| Dec 5, 2024 | Goldman Sachs | DOWNGRADE | Neutral | Sell |
| Nov 14, 2024 | Wolfe Research | INITIATE | — | Peer Perform |
| Nov 8, 2024 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Nov 8, 2024 | William Blair | DOWNGRADE | Outperform | Market Perform |
| Nov 8, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Oct 8, 2024 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Aug 27, 2024 | Wells Fargo | INITIATE | — | Overweight |
| Aug 16, 2024 | RBC Capital | REITERATE | Outperform | Outperform |
| Aug 13, 2024 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Aug 8, 2024 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Aug 8, 2024 | UBS | MAINTAIN | Neutral | Neutral |
| Jul 9, 2024 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| May 9, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Apr 10, 2024 | Craig-Hallum | INITIATE | — | Buy |
| Feb 23, 2024 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 23, 2024 | Stifel | MAINTAIN | Buy | Buy |
| Dec 12, 2023 | B of A Securities | UPGRADE | Neutral | Buy |
| Nov 9, 2023 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Nov 9, 2023 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Aug 9, 2023 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Aug 8, 2023 | Deutsche Bank | MAINTAIN | Buy | Buy |
| Aug 8, 2023 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Aug 8, 2023 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Aug 8, 2023 | Baird | MAINTAIN | Outperform | Outperform |
| Aug 8, 2023 | Credit Suisse | MAINTAIN | Neutral | Neutral |
| Aug 8, 2023 | Keybanc | DOWNGRADE | Overweight | Sector Weight |
| May 23, 2023 | Credit Suisse | DOWNGRADE | Outperform | Neutral |
| May 10, 2023 | Goldman Sachs | MAINTAIN | — | Neutral |
| May 10, 2023 | Morgan Stanley | MAINTAIN | — | Overweight |
| May 9, 2023 | RBC Capital | MAINTAIN | — | Outperform |
| May 9, 2023 | Goldman Sachs | DOWNGRADE | Buy | Neutral |
| May 9, 2023 | Deutsche Bank | MAINTAIN | — | Buy |
| May 9, 2023 | Credit Suisse | MAINTAIN | — | Outperform |
| Feb 24, 2023 | Morgan Stanley | MAINTAIN | — | Overweight |
| Feb 23, 2023 | Baird | MAINTAIN | — | Outperform |
| Feb 23, 2023 | Credit Suisse | MAINTAIN | — | Outperform |
| Feb 23, 2023 | Keybanc | MAINTAIN | — | Overweight |
| Jan 17, 2023 | Goldman Sachs | MAINTAIN | — | Buy |
| Jan 5, 2023 | UBS | DOWNGRADE | Buy | Neutral |
| Dec 14, 2022 | Deutsche Bank | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 6 | 0 | 0 | 63% | |
| May 1, 2026 | 4 | 6 | 6 | 0 | 0 | 63% | |
| Apr 1, 2026 | 4 | 6 | 7 | 0 | 0 | 59% | |
| Mar 1, 2026 | 4 | 6 | 7 | 0 | 0 | 59% | |
| Feb 1, 2026 | 4 | 6 | 7 | 0 | 0 | 59% | |
| Jan 1, 2026 | 4 | 6 | 7 | 0 | 0 | 59% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
MRVI Q1 2026 Earnings After Market Close — 2026-05-07
Feb 25, 2026
earnings_calendar
MRVI Q4 2025 Earnings After Market Close — 2026-02-25